US Patent

US11975006 — Liquid oral formulations for tadalafil

Method of Use · Assigned to Liqmeds Worldwide Ltd · Expires 2038-12-24 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects liquid oral formulations of the PDE V inhibitor tadalafil, used to treat conditions such as pulmonary arterial hypertension and erectile dysfunction.

USPTO Abstract

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3397 — Cialis

Patent Metadata

Patent number
US11975006
Jurisdiction
US
Classification
Method of Use
Expires
2038-12-24
Drug substance claim
No
Drug product claim
Yes
Assignee
Liqmeds Worldwide Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.